Zai Lab (ZLAB) Long-Term Deferred Tax (2025 - 2026)

Zai Lab (ZLAB) posted Long-Term Deferred Tax of $3.4 million for Q1 2026, up 1.59% sequentially from $3.4 million in Q4 2025.

Analysis

Zai Lab (ZLAB) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends

Zai Lab has reported Long-Term Deferred Tax for 2 years, with the latest figure at $3.4 million in Q1 2026.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (changed N/A YoY) and the FY2025 annual result came in at $3.4 million, changed N/A from the prior year.
Long-Term Deferred Tax grew to $3.4 million in Q1 2026 per ZLAB's latest filing, from $3.4 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $3.4 million in Q1 2026 and troughed at $3.4 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.78 Bn	130.92 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.50 Bn	77.51 Bn	3.93 Bn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn
4	Moderna	58.06 Bn	52.92 Bn	52.00 Mn
5	Revolution Medicines	44.04 Bn	44.04 Bn	-
6	BeOne Medicines	40.04 Bn	34.94 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn
8	Royalty Pharma	28.41 Bn	27.57 Bn	-
9	Insmed	27.42 Bn	26.26 Bn	358.27 Mn
10	Zai Lab	2.93 Bn	2.22 Bn	58.15 Mn

Historic Data

Download Data